


Curriculum Vitae

Name	Chan-Young Ock	
Current Position & Affiliation	Bang & Ock Consulting	
Country	Republic of Korea	

Educational Background

- Mar/2014~Feb/2018 Ph.D.,
Seoul National University College of Medicine,
Seoul, Korea
- Mar/2002~Feb/2008 M.D.,
Seoul National University College of Medicine,
Seoul, Korea

Professional Experience

- Mar/2020~Present **Chief Medical Officer**
in Bang & Ock Consulting
- Sep/2019~Present **Chief Medical Officer**
in Lunit
- Mar/2018~Aug/2019 **Clinical Assistant Professor**
in Medical Oncology,
Seoul National University Hospital
- Mar/2017~Feb/2018 **Chief Medical Officer**
in Medpacto & **Medical Director**
in Theragen Etex Bio
- Mar/2016~Feb/2017 **Clinical Fellowship**
in Medical Oncology,
Seoul National University Hospital
- Mar/2011~Feb/2016 **Internship/Resident**
in Internal Medicine,
Seoul National University Hospital

Main Scientific Publications

1. **Ock CY**, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. *Nat Commun* 2017 Oct 19;8(1):1050.
2. **Ock CY**, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration. *Clin Cancer Res* 2016 May 1;22(9):2261-70.
3. An E*, **Ock CY***, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Liao WL, Cecchi F, Blackler A, Thyparambil S, Kim WH, Burrows J, Hembrough T, Catenacci D, Oh DY, Bang YJ. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. *Ann Oncol* 2017 Jan 1;28(1):110-115.
4. **Ock CY**, Lee KW, Kim JW, Kim JS, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Kim WH, Bang YJ, Oh DY. Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer. *Clin Cancer Res* 2015 Jun 1;21(11):2520-9.
5. Park C, Na KJ, Choi H*, **Ock CY*** et al. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. *Theranostics* 2020 Aug 29;10(23):10838-10848.
6. Park C, Jeong K, Park JH, Jung S, Bae JM, Kim K*, **Ock CY*** et al. Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. *Cancer Immunol Immunother* 2020 Nov 24.